<DOC>
	<DOCNO>NCT02197169</DOCNO>
	<brief_summary>Glioblastoma ( GBM ) gliosarcoma ( GS ) common aggressive form malignant primary brain tumor adult resistant conventional therapy . The purpose Phase Ib study evaluate well recurrent glioblastoma gliosarcoma tumor respond one injection DNX-2401 , genetically modify , conditionally replicative oncolytic human-derived adenovirus . DNX-2401 deliver directly tumor may establish active infection replicate kill tumor cell .</brief_summary>
	<brief_title>DNX-2401 With Interferon Gamma ( IFN-γ ) Recurrent Glioblastoma Gliosarcoma Brain Tumors</brief_title>
	<detailed_description>Enrollment complete randomized portion study ongoing evaluation tumor response safety . No additional subject randomize receive interferon gamma ( IFN-γ ) . The non-randomized portion study open screen enrollment . Eligible subject receive single intratumoral injection DNX-2401 recurrent glioblastoma gliosarcoma brain tumor use Alcyone MEMS Cannula ( AMC™ ) System ( cannula ) . Tumor response safety evaluate . After receive DNX-2401 , subject return clinic study visit regular interval safety monitoring , MRI scan assessment 18 month . Thereafter , follow closely safety survival .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Glioblastoma gliosarcoma first second recurrence Documented tumor recurrence progression fail prior surgical resection , chemotherapy , radiation Tumor size great equal 1.0 cm two perpendicular diameter Not undergo surgical resection gross total resection possible Karnofsky Performance Status great equal 70 % Multiple intracranial malignant glioma lesion Tumor location involvement would result risk ventricular penetration tumor injection Tumor involve hemisphere involve subependyma suspect cerebrospinal fluid dissemination Tumor involve brain stem Documented extracranial metastasis Inability undergo MRI Pregnant nursing female Any medical condition precludes surgery necessary administer DNX2401 tumor use cannula Immunocompromised subject autoimmune condition , active hepatitis positive human immunodeficiency virus ( HIV ) LiFraumeni Syndrome Other protocoldefined inclusion/exclusion criterion may apply outlined relevant protocol version</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Brain</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Brain Neoplasms</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Central Nervous System Neoplasms</keyword>
	<keyword>CNS</keyword>
	<keyword>Conditionally Replication-Competent Adenovirus</keyword>
	<keyword>DNX-2401</keyword>
	<keyword>Delta-24-RGD</keyword>
	<keyword>Glioma</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Interferon gamma</keyword>
	<keyword>Malignant brain tumor</keyword>
	<keyword>Neoplasms , Neuroepithelial</keyword>
	<keyword>Neuroectodermal Tumors</keyword>
	<keyword>Neoplasms , Germ Cell Embryonal</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>Neoplasms , Nerve Tissue</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Alcyone Lifesciences</keyword>
	<keyword>AMC™</keyword>
	<keyword>Cannula</keyword>
	<keyword>Alcyone MEMS Cannula ( AMC™ ) System</keyword>
</DOC>